| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 378 | 2022 |
| Deep learning algorithm predicts diabetic retinopathy progression in individual patients F Arcadu, F Benmansour, A Maunz, J Willis, Z Haskova, M Prunotto NPJ digital medicine 2 (1), 92, 2019 | 296 | 2019 |
| Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial AM Khanani, SS Patel, PJ Ferrone, A Osborne, J Sahni, S Grzeschik, ... JAMA ophthalmology 138 (9), 964-972, 2020 | 168 | 2020 |
| Vision-related functional burden of diabetic retinopathy across severity levels in the United States JR Willis, QV Doan, M Gleeson, Z Haskova, P Ramulu, L Morse, ... JAMA ophthalmology 135 (9), 926-932, 2017 | 165 | 2017 |
| Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy CC Wykoff, DA Eichenbaum, DB Roth, L Hill, AE Fung, Z Haskova Ophthalmology Retina 2 (10), 997-1009, 2018 | 106 | 2018 |
| Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin S Srivastava, D Pelloso, H Feng, L Voiles, D Lewis, Z Haskova, ... Cancer immunology, immunotherapy 62, 1073-1082, 2013 | 92 | 2013 |
| Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-γ-inducible protein of 10 kDa in vitro and … G Boulday, Z Haskova, MEJ Reinders, S Pal, DM Briscoe The Journal of Immunology 176 (5), 3098-3107, 2006 | 82 | 2006 |
| Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration CD Regillo, BG Busbee, AC Ho, B Ding, Z Haskova American journal of ophthalmology 160 (5), 1014-1023. e2, 2015 | 81 | 2015 |
| Deep learning predicts OCT measures of diabetic macular thickening from color fundus photographs F Arcadu, F Benmansour, A Maunz, J Michon, Z Haskova, D McClintock, ... Investigative ophthalmology & visual science 60 (4), 852-857, 2019 | 79 | 2019 |
| CD4+ T CELLS ARE CRITICAL FOR CORNEAL, BUT NOT SKIN, ALLOGRAFT REJECTION1 Z Haskova, N Usiu, JS Pepose, TA Ferguson, PM Stuart Transplantation 69 (4), 483-487, 2000 | 70 | 2000 |
| Spectral-domain OCT predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion G Yiu, RJ Welch, Y Wang, Z Wang, PW Wang, Z Haskova Ophthalmology Retina 4 (1), 67-76, 2020 | 68 | 2020 |
| YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale N Eter, RP Singh, F Abreu, K Asik, K Basu, C Baumal, A Chang, KG Csaky, ... Ophthalmology Science 2 (1), 100111, 2022 | 48 | 2022 |
| Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection P Hamrah, Z Haskova, AW Taylor, Q Zhang, BR Ksander, MR Dana Transplantation 88 (2), 180-187, 2009 | 45 | 2009 |
| Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials TY Wong, Z Haskova, K Asik, CR Baumal, KG Csaky, N Eter, JA Ives, ... Ophthalmology 131 (6), 708-723, 2024 | 43 | 2024 |
| Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of RIDE and RISE studies JK Sun, P Wang, S Taylor, Z Haskova Ophthalmology 126 (5), 712-720, 2019 | 37 | 2019 |
| Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection Z Haskova, A Izawa, AG Contreras, E Flynn, G Boulday, DM Briscoe Transplantation 83 (12), 1595-1601, 2007 | 34 | 2007 |
| Effect of metalloprotease inhibitors on corneal allograft survival PM Stuart, F Pan, X Yin, Z Haskova, S Plambeck, TA Ferguson Investigative ophthalmology & visual science 45 (4), 1169-1173, 2004 | 34 | 2004 |
| Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials MA Zarbin, C Dunger-Baldauf, Z Haskova, P Koovejee, MC Mousseau, ... JAMA ophthalmology 135 (5), 424-431, 2017 | 33 | 2017 |
| An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection1 Z Haskova, TJ Sproule, DC Roopenian, BR Ksander Transplantation 75 (8), 1368-1374, 2003 | 31 | 2003 |
| A CIITA‐independent pathway that promotes expression of endogenous rather than exogenous peptides in immune‐privileged sites CV Arancibia‐Cárcamo, H Osawa, HA Arnett, Z Háskova, AJT George, ... European journal of immunology 34 (2), 471-480, 2004 | 29 | 2004 |